DNA methylation profiles in chronic lymphocytic leukemia
patients treated with chemoimmunotherapy

J 2019

DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy

TSAGIOPOULOU, M., N. PAPAKONSTANTINOU, T. MOYSIADIS, L. MANSOURI, V. LJUNGSTROM et. al.

Basic information

Original name

DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy

Authors

TSAGIOPOULOU, M. (300 Greece), N. PAPAKONSTANTINOU (300 Greece), T. MOYSIADIS (300 Greece), L. MANSOURI (752 Sweden), V. LJUNGSTROM (752 Sweden), M. DURAN-FERRER (724 Spain), A. MALOUSI (300 Greece), A.C. QUEIROS (724 Spain), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), S. BHOI (752 Sweden), P. KOLLIA (300 Greece), D. OSCIER (826 United Kingdom of Great Britain and Northern Ireland), A. ANAGNOSTOPOULOS (300 Greece), L. TRENTIN (380 Italy), M. RITGEN (276 Germany), Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution), N. STAVROYIANNI (300 Greece), P. GHIA (380 Italy), J.I. MARTIN-SUBERO (724 Spain), C. POTT (380 Italy), R. ROSENQUIST (752 Sweden) and K. STAMATOPOULOS (300 Greece)

Edition

CLINICAL EPIGENETICS, LONDON, BMC, 2019, 1868-7075

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.028

RIV identification code

RIV/00216224:14740/19:00113009

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.1186/s13148-019-0783-1

UT WoS

000501362500005

Keywords in English

DNA methylation; Chemoimmunotherapy; CLL; Microarray analysis; Relapse

Abstract

V originále

Background In order to gain insight into the contribution of DNA methylation to disease progression of chronic lymphocytic leukemia (CLL), using 450K Illumina arrays, we determined the DNA methylation profiles in paired pre-treatment/relapse samples from 34 CLL patients treated with chemoimmunotherapy, mostly (n = 31) with the fludarabine-cyclophosphamide-rituximab (FCR) regimen. Results The extent of identified changes in CLL cells versus memory B cells from healthy donors was termed "epigenetic burden" (EB) whereas the number of changes between the pre-treatment versus the relapse sample was termed "relapse changes" (RC). Significant (p < 0.05) associations were identified between (i) high EB and short time-to-first-treatment (TTFT); and, (ii) few RCs and short time-to-relapse. Both the EB and the RC clustered in specific genomic regions and chromatin states, including regulatory regions containing binding sites of transcription factors implicated in B cell and CLL biology. Conclusions Overall, we show that DNA methylation in CLL follows different dynamics in response to chemoimmunotherapy. These epigenetic alterations were linked with specific clinical and biological features.

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

TSAGIOPOULOU, M., N. PAPAKONSTANTINOU, T. MOYSIADIS, L. MANSOURI, V. LJUNGSTROM, M. DURAN-FERRER, A. MALOUSI, A.C. QUEIROS, Karla PLEVOVÁ, S. BHOI, P. KOLLIA, D. OSCIER, A. ANAGNOSTOPOULOS, L. TRENTIN, M. RITGEN, Šárka POSPÍŠILOVÁ, N. STAVROYIANNI, P. GHIA, J.I. MARTIN-SUBERO, C. POTT, R. ROSENQUIST and K. STAMATOPOULOS. DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy. CLINICAL EPIGENETICS. LONDON: BMC, 2019, vol. 11, No 1, p. 177-188. ISSN 1868-7075. Available from: https://dx.doi.org/10.1186/s13148-019-0783-1.

@article{1625079,
   author = {Tsagiopoulou, M. and Papakonstantinou, N. and Moysiadis, T. and Mansouri, L. and Ljungstrom, V. and DuranandFerrer, M. and Malousi, A. and Queiros, A.C. and Plevová, Karla and Bhoi, S. and Kollia, P. and Oscier, D. and Anagnostopoulos, A. and Trentin, L. and Ritgen, M. and Pospíšilová, Šárka and Stavroyianni, N. and Ghia, P. and MartinandSubero, J.I. and Pott, C. and Rosenquist, R. and Stamatopoulos, K.},
   article_location = {LONDON},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s13148-019-0783-1},
   keywords = {DNA methylation; Chemoimmunotherapy; CLL; Microarray analysis; Relapse},
   language = {eng},
   issn = {1868-7075},
   journal = {CLINICAL EPIGENETICS},
   title = {DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy},
   url = {https://clinicalepigeneticsjournal.biomedcentral.com/track/pdf/10.1186/s13148-019-0783-1},
   volume = {11},
   year = {2019}
}

TY  - JOUR
ID  - 1625079
AU  - Tsagiopoulou, M. - Papakonstantinou, N. - Moysiadis, T. - Mansouri, L. - Ljungstrom, V. - Duran-Ferrer, M. - Malousi, A. - Queiros, A.C. - Plevová, Karla - Bhoi, S. - Kollia, P. - Oscier, D. - Anagnostopoulos, A. - Trentin, L. - Ritgen, M. - Pospíšilová, Šárka - Stavroyianni, N. - Ghia, P. - Martin-Subero, J.I. - Pott, C. - Rosenquist, R. - Stamatopoulos, K.
PY  - 2019
TI  - DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy
JF  - CLINICAL EPIGENETICS
VL  - 11
IS  - 1
SP  - 177
EP  - 177
PB  - BMC
SN  - 18687075
KW  - DNA methylation
KW  - Chemoimmunotherapy
KW  - CLL
KW  - Microarray analysis
KW  - Relapse
UR  - https://clinicalepigeneticsjournal.biomedcentral.com/track/pdf/10.1186/s13148-019-0783-1
L2  - https://clinicalepigeneticsjournal.biomedcentral.com/track/pdf/10.1186/s13148-019-0783-1
N2  - Background In order to gain insight into the contribution of DNA methylation to disease progression of chronic lymphocytic leukemia (CLL), using 450K Illumina arrays, we determined the DNA methylation profiles in paired pre-treatment/relapse samples from 34 CLL patients treated with chemoimmunotherapy, mostly (n = 31) with the fludarabine-cyclophosphamide-rituximab (FCR) regimen. Results The extent of identified changes in CLL cells versus memory B cells from healthy donors was termed "epigenetic burden" (EB) whereas the number of changes between the pre-treatment versus the relapse sample was termed "relapse changes" (RC). Significant (p < 0.05) associations were identified between (i) high EB and short time-to-first-treatment (TTFT); and, (ii) few RCs and short time-to-relapse. Both the EB and the RC clustered in specific genomic regions and chromatin states, including regulatory regions containing binding sites of transcription factors implicated in B cell and CLL biology. Conclusions Overall, we show that DNA methylation in CLL follows different dynamics in response to chemoimmunotherapy. These epigenetic alterations were linked with specific clinical and biological features.
ER  -

TSAGIOPOULOU, M., N. PAPAKONSTANTINOU, T. MOYSIADIS, L. MANSOURI, V. LJUNGSTROM, M. DURAN-FERRER, A. MALOUSI, A.C. QUEIROS, Karla PLEVOVÁ, S. BHOI, P. KOLLIA, D. OSCIER, A. ANAGNOSTOPOULOS, L. TRENTIN, M. RITGEN, Šárka POSPÍŠILOVÁ, N. STAVROYIANNI, P. GHIA, J.I. MARTIN-SUBERO, C. POTT, R. ROSENQUIST and K. STAMATOPOULOS. DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy. \textit{CLINICAL EPIGENETICS}. LONDON: BMC, 2019, vol.~11, No~1, p.~177-188. ISSN~1868-7075. Available from: https://dx.doi.org/10.1186/s13148-019-0783-1.

Detailed Information on Publication Record